Assisted Reproductive Technology Market Size, Share, Growth & Trend Analysis Report, 2032

Summary
Market Landscape
Methodology
Table of Content

Global Assisted Reproductive Technology Market Size, Share, Growth, & Trend Analysis Report By type (In-Vitro Fertilization, Artificial Insemination), By End-use, By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) and Forecasts 2024 – 2032

Assisted Reproductive Technology (ART) refers to medical treatments and procedures that help people conceive a child when they are having difficulty doing so naturally. This includes methods like in vitro fertilization (IVF), where eggs and sperm are combined outside the body, and then implanted into the woman's uterus. ART also covers other techniques like egg freezing and sperm donation

The Global Food Traceability Market was valued at more than USD 20 billion in 2024 and is projected to reach USD XX billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of XX% during the forecast period from 2025 to 2032.

Industry Trends

The increasing prevalence of infertility is becoming a significant driver in the global market for Assisted Reproductive Technologies (ART). Modern lifestyle changes, such as unhealthy diets, stress, and a sedentary lifestyle, are contributing to hormonal imbalances and fertility issues, leading to more people seeking ART services. Environmental pollutants and toxins are also major factors affecting reproductive health. Furthermore, as more individuals choose to start families later in life, age-related fertility issues have added to the demand for ART solutions.

Delayed parenthood, driven by personal career growth, financial stability, and higher education, has also contributed to a rise in ART demand. While older individuals have the advantage of emotional maturity and financial readiness, fertility declines as age increases. This has led many older individuals to turn to ART procedures to fulfill their desire for parenthood.

On the opportunity front, there’s a growing awareness and acceptance of ART, with many individuals and couples actively seeking fertility treatments. Social acceptance of these procedures is expanding, as ART is increasingly seen as a viable solution for those facing infertility challenges. Male infertility, once often overlooked, has gained recognition, resulting in more research and development efforts to address this issue, creating further market opportunities.

Advancements in ART technology, such as genetic testing, improved embryo culture techniques, and embryo selection, are improving success rates and offering patients better outcomes. These innovations have expanded the possibilities in infertility treatments, making ART more effective and accessible, thus driving the growth of the market.

However, challenges remain. The high cost of ART procedures remains a significant barrier, as the necessary medical equipment, specialized treatments, and trained professionals can make the process unaffordable for many. With multiple cycles often required to achieve a successful pregnancy, financial stress can add to the difficulty.

Industry Expert’s Opinion

Dr Muskaan Chhabra, IVF Specialist, Birla Fertility & IVF, India

“Steady advancements in assisted reproductive technologies (ART) and their implications for human reproduction depicts a promising future of fertility in 2025 and beyond. Driven by the evolving socio-demographic trends, there has been a significant increase in the demand for in vitro fertilization (IVF) and the fast-paced advancements in reproductive technology is further expected to reshape how humans conceive. Over the next decade, we are likely to see significant improvements in IVF success rates, personalized treatments, and ethical considerations surrounding fertility care. It is likely that in the near future, as many as 10% of all children will be conceived through IVF in many parts of the world.”

TT Consultants’ Perspective

The Assisted Reproductive Technology (ART) market is experiencing strong growth, driven by rising infertility rates, technological advancements, and increasing demand for fertility preservation solutions like egg and sperm freezing. Companies are focusing on AI integration, patient education, and expanding their service offerings.

TT Consultants highlights the importance of targeting emerging markets, investing in cutting-edge cryopreservation and IVF technologies, and forming strategic partnerships. Our insights suggest that the key to success lies in improving patient experience, leveraging AI for better outcomes, and expanding reach in developing regions.

Market Segmentation

1. By Type (In-Vitro Fertilization, Artificial Insemination)

The global market for assisted reproductive technologies (ART) is predominantly driven by the in vitro fertilization (IVF) segment, which remains the largest within the industry. Within IVF, procedures are further divided based on whether the eggs are fresh or frozen, and whether a donor is involved. Among these, the frozen non-donor segment has become particularly popular due to its effectiveness. This procedure is often chosen when the woman’s eggs are healthy but issues such as male infertility or fallopian tube problems prevent natural conception. The growing success rates and benefits of frozen non-donor procedures have made them a preferred choice for many.

In recent years, the number of IVF cycles using frozen non-donor eggs or embryos has seen significant growth, reflecting a shift towards this method. The flexibility of using frozen embryos or eggs, which have been carefully selected and stored, provides greater control over the timing and success of the procedure. This trend highlights a preference for ensuring the best possible chances of success, especially for individuals with specific fertility challenges.

Looking forward, artificial insemination is expected to experience the highest growth within the ART market. This method, including types such as intrauterine insemination (IUI), is commonly used for minor fertility issues and is especially popular among same-sex couples or single women. While the success rates for artificial insemination can vary, it continues to show promising results, particularly for women under 35. Many women undergoing intrauterine insemination conceive within the first few cycles, which enhances its appeal for those seeking less invasive fertility treatments.

2. By End Use (Hospitals, Clinics)

The fertility clinics and specialized facilities segment has been the dominant player, accounting for the largest share of the market. This segment continues to lead due to the rising number of infertility cases and the need for specialized environments to provide ART services. The growth in this segment is expected to continue at a rapid pace, driven by the increasing demand for dedicated centers that focus solely on fertility treatments.

One reason for the dominance of fertility clinics is their expertise and focus on ART procedures, which allow them to offer tailored and effective solutions for individuals seeking fertility treatments. Additionally, the specialization and advanced technologies available at these clinics make them the preferred choice for many.

On the other hand, hospitals and other settings, while still important, are expected to see more growth in low- and middle-income countries. In these regions, the lack of specialized fertility clinics means that multispecialty hospitals often serve as the primary option for ART services. These hospitals can offer fertility treatments as part of a broader range of medical services, making them more accessible to a larger population. While fertility clinics remain the preferred choice in more developed markets, hospitals provide a practical solution where specialized infrastructure is lacking.

3. By Region (North America, Europe, APAC, Latin America, MEA)

Europe stands out as the most prominent region in the global assisted reproductive technology (ART) market. Its leadership is driven by substantial investments, favorable regulations, and a well-established healthcare infrastructure, making it the largest market. The region continues to attract attention due to its consistent advancements in reproductive healthcare and accessibility to cutting-edge technologies. These factors collectively make Europe a hub for ART services, further boosting its growth potential.

Asia Pacific, on the other hand, is emerging as a rapidly growing market. Increasing awareness about infertility treatments, rising demand for ART services, and significant investments in healthcare are fueling its expansion. Countries like China, India, and Japan play a pivotal role in this growth due to their large populations and expanding middle classes. As more individuals prioritize reproductive health, the demand for ART in the region continues to surge. Governments and private sectors are also focusing on improving access to fertility treatments, adding momentum to this growth.

In contrast, North America is considered a mature market for ART. With widespread awareness, high adoption rates, and robust investment in reproductive health, the region maintains its strong position. Established healthcare systems and advancements in ART technologies have made treatments widely accessible, supporting consistent market performance. The region’s focus on innovation and patient-centric care further reinforces its dominance in the global landscape.

The Middle East and Africa, however, face unique challenges in the ART market. Limited access to healthcare services, coupled with cultural and regulatory barriers, hinders the adoption of ART in these regions. Despite these obstacles, there are opportunities for growth as healthcare infrastructure improves and awareness about infertility treatments rises. With focused efforts to address these barriers, the region holds potential for future market expansion.

Competitive Scenario

The assisted reproductive technology (ART) market includes key players such as CooperSurgical, Inc., Vitrolife AB, FUJIFILM Irvine Scientific, Cryolab Ltd., Ferring Pharmaceuticals, Merck KGaA, European Sperm Bank, Bloom Fertility Centre, ORIGIO A/S, Cook Medical Inc., Thermo Fisher Scientific, Inc., Genea Biomedx, Progyny Inc., Microm UK Ltd., and Parallabs Limited. These companies are actively contributing to advancements in fertility treatments through innovative solutions, specialized services, and cutting-edge technologies, making significant impacts on the global ART market.

Recent Developments and Strategic Activities:

In December 2024, Astorg has merged Hamilton Thorne and Cook Medical’s Reproductive Health business to create a global leader in Assisted Reproductive Technology (ART) and in vitro fertilization (IVF), offering a comprehensive portfolio of innovative products and services to fertility clinics in over 115 countries. Backed by Astorg’s expertise in healthcare investments, the new entity, led by CEO Wil Boren and CFO/COO Jimmy DeStephens, aims to address rising fertility challenges by improving treatment accessibility and outcomes. This strategic consolidation strengthens Astorg’s MedTech portfolio, positioning the combined business as a key player in advancing global fertility solutions.
In August 2024, ZyMōt Fertility Inc.’s sperm separation device, a groundbreaking innovation in assistive reproductive technology (ART), gained attention for its ability to improve IVF success rates by precisely selecting healthy sperm and minimizing cell damage. This advancement addresses the growing demand for more effective and less invasive fertility treatments, enhancing reproductive health outcomes. The acquisition by CooperSurgical expands access to this cutting-edge technology, further impacting the field of assisted reproduction.
In June 2022, Inception Fertility launched HavenCryo™, an advanced cryopreservation solution for reproductive tissues. HavenCryo allows patients to store their reproductive tissues for an indefinite period with state-of-the-art storage equipment and security technologies. The solution provides greater flexibility for patients, including those at the end of their ART journey, to preserve their oocytes, sperm, and embryos. The strategic location of HavenCryo in San Antonio, Texas, ensures minimal risk of natural disaster interference, offering added peace of mind for patients looking to store their reproductive tissue long-term.